Mesenchymal Stromal Cells: Heterogeneity and Therapeutical Applications

Ouzin, Meryem; Kögler, Gesine

doi:10.3390/cells12162039

Cited by 17 publications

(2 citation statements)

References 158 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The immunomodulatory function of MSC-derived IPCs can be further enhanced to overcome autoimmune reactions in individuals with T1DM [ 111 – 114 ]. The downside of MSC clinical applications is their heterogeneity which is dependent on the source of their procurement and the donor-to-donor variability [ 115 , 116 ]. Attempts toward their standardization are currently under exploration [ 117 ].…”

Section: Discussionmentioning

confidence: 99%

Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration

Ghoneim,

Gabr,

El-Halawani

et al. 2024

Stem Cell Res Ther

View full text Add to dashboard Cite

Over the past decade, there had been progress in the development of cell therapy for insulin-dependent diabetes. Nevertheless, important hurdles that need to be overcome still remain. Protocols for the differentiation of pluripotent stem cells into pancreatic progenitors or fully differentiated β-cells have been developed. The resulting insulin-producing cells can control chemically induced diabetes in rodents and were the subject of several clinical trials. However, these cells are immunogenic and possibly teratogenic for their transplantation, and an immunoisolation device and/or immunosuppression is needed. A growing number of studies have utilized genetic manipulations to produce immune evasive cells. Evidence must be provided that in addition to the expected benefit, gene manipulations should not lead to any unforeseen complications. Mesenchymal stem/stromal cells (MSCs) can provide a viable alternative. MSCs are widely available from many tissues. They can form insulin-producing cells by directed differentiation. Experimentally, evidence has shown that the transplantation of allogenic insulin-producing cells derived from MSCs is associated with a muted allogeneic response that does not interfere with their functionality. This can be explained by the immunomodulatory functions of the MSC subpopulation that did not differentiate into insulin-producing cells. Recently, exosomes derived from naive MSCs have been used in the experimental domain to treat diabetes in rodents with varying degrees of success. Several mechanisms for their beneficial functions were proposed including a reduction in insulin resistance, the promotion of autophagy, and an increase in the T regulatory population. However, euglycemia was not achieved in any of these experiments. We suggest that exosomes derived from β-cells or insulin-producing cells (educated) can provide a better therapeutic effect than those derived from undifferentiated cells.

show abstract

Section: Discussionmentioning

confidence: 99%

Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration

Ghoneim,

Gabr,

El-Halawani

et al. 2024

Stem Cell Res Ther

View full text Add to dashboard Cite

show abstract

“…The varied nature of the MSC population and the requirement to identify functionally distinct subgroups present a challenge to understanding the function of MSCs in the HSC niche. In human tissue, MSCs are recognized based on the presence of CD44, CD90, CD105, CD73, and CD106 and the lack of hematopoietic and endothelial (CD31) cell markers ( Dominici et al, 2006 ; Schwab and Gargett, 2007 ; Crisan et al, 2008 ; Ouzin and Kogler, 2023 ). However, the MSCs isolated from different sources exhibit differential gene expression patterns, and over the years, a significant number of markers have been proposed to aid in the isolation of MSCs from their surroundings.…”

Section: Identity and Characterization Of Bm-mscsmentioning

confidence: 99%

Mesenchymal stromal cells, metabolism, and mitochondrial transfer in bone marrow normal and malignant hematopoiesis

Singh,

Prasad,

Cancelas

2023

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Hematopoietic stem cell (HSC) transplantation-based treatments are in different phases of clinical development, ranging from current therapies to a promise in the repair and regeneration of diseased tissues and organs. Mesenchymal stromal/stem cells (MSCs), which are fibroblast-like heterogeneous progenitors with multilineage differentiation (osteogenic, chondrogenic, and adipogenic) and self-renewal potential, and exist in the bone marrow (BM), adipose, and synovium, among other tissues, represent one of the most widely used sources of stem cells in regenerative medicine. MSCs derived from bone marrow (BM-MSCs) exhibit a variety of traits, including the potential to drive HSC fate and anti-inflammatory and immunosuppressive capabilities via paracrine activities and interactions with the innate and adaptive immune systems. The role of BM-MSC-derived adipocytes is more controversial and may act as positive or negative regulators of benign or malignant hematopoiesis based on their anatomical location and functional crosstalk with surrounding cells in the BM microenvironment. This review highlights the most recent clinical and pre-clinical findings on how BM-MSCs interact with the surrounding HSCs, progenitors, and immune cells, and address some recent insights on the mechanisms that mediate MSCs and adipocyte metabolic control through a metabolic crosstalk between BM microenvironment cells and intercellular mitochondrial transfer in normal and malignant hematopoiesis.

show abstract

Mesenchymal Stem Cells

Yildirim

2024

Dental Pulp Derived Mesenchymal Stromal Cells

View full text Add to dashboard Cite

Mesenchymal Stromal Cells: Heterogeneity and Therapeutical Applications

Cited by 17 publications

References 158 publications

Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration

Current status of stem cell therapy for type 1 diabetes: a critique and a prospective consideration

Mesenchymal stromal cells, metabolism, and mitochondrial transfer in bone marrow normal and malignant hematopoiesis

Mesenchymal Stem Cells

Contact Info

Product

Resources

About